Latest Administration News

LTR Pharma highlights SPONTAN's 5x faster absorption and validated safety, backed by over 1,000 Australian prescriptions and strategic partnerships as it targets FDA approval and US market entry.

Resmed delivered a robust Q3 FY2026 with 11% revenue growth, margin expansion, and a 21% jump in non-GAAP EPS, while announcing a new U.S. distribution centre and a $0.60 dividend.

Aldoro Resources has defined high-priority gold targets at its Damara Gold Project and confirmed significant rare earth and associated mineralisation at Kameelburg, with drilling and metallurgical progress underpinning its dual-commodity strategy.

RareX Limited has advanced its rare earths ambitions by securing a key mining lease at Cummins Range, appointing a strategic board member, and raising $5 million to fund exploration and development.

Recce Pharmaceuticals bolsters its clinical and commercial pipeline with a $5.3 million AUD R&D tax rebate, a second U.S. Army research agreement for its RECCE 327 Gel, and a key patent granted in Brazil, while progressing Phase 3 trials in Indonesia.

Evion Group has secured key approvals from Madagascar’s Ministry of Mines to convert exploration permits into mining permits for its Maniry Graphite Project, backed by significant EU funding and US trade initiatives. Meanwhile, its Indian joint venture progresses a major graphite plant expansion to meet growing demand.

Chariot Resources advances its Nigerian lithium acquisition with six licences transferred and spodumene confirmed in samples, while raising A$2.15 million and securing a A$3.5 million loan refinancing.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Cynata Therapeutics is on the cusp of releasing critical data from its Phase 2 aGvHD and Phase 3 osteoarthritis trials in Q2 2026, while managing a tight cash runway and preparing for a capital raising.

Alterity Therapeutics secures FDA backing on key Phase 3 elements for ATH434 in Multiple System Atrophy, bolstered by fresh Phase 2 data showing slowed disease progression and strategic leadership hires.

Alpha HPA Limited reports robust progress on its HPA First Project Stage 2, backed by a $225 million capital raise, while securing significant demand upgrades from Japanese semiconductor customers.

Terra Critical Minerals has established a US foothold with the True American Tungsten Project acquisition while progressing key Australian and Canadian critical metals projects, positioning for upcoming drilling campaigns.